Skip to main content

Our Companies



aims to enhance articular cartilage regeneration through the development of a biocompatible, flexible electronic mesh that promotes the restoration of articular cartilage.

The Need

Articular cartilage lesions are a common pathology of the knee joint, associated with pain, loss of function and long-term complications. The most common treatments include debridement and marrow tapping techniques; however, these often result in inadequate repair and scar formation and high reoperation rate (42.1% 1). There is a need for new technologies that can stimulate and restore cartilage tissue.


Development Stage


Articular cartilage has limited regenerative capacity, but uses intrinsic repair mechanisms, that cans potentially be electrically stimulated and promoted for peak performance. Vigorous Medical is developing a porous, biocompatible, soft, and flexible electronic mesh implant that will interface with articular cartilage lesion and stimulate innate repair mechanisms.

Prof. Tal Dvir

Prof. Tal Dvir. Tal Dvir is a Professor at Tel Aviv University in the Department of Biotechnology and the Department of Biomedical Engineering. Prof. Dvir is also the Director of Tel Aviv University’s Center for Nanoscience and Nanotechnology. His multi-disciplinary research focuses on the development of new technologies, based on cutting-edge materials and combining stem cells for engineering and regenerating diseased tissues and organs. Among the developed technologies are 3D printing of vascularized tissues and organs, engineered tissues with soft and flexible, built-in electronics, and the development of personalized engineered tissue implants

The Market Opportunity

The global knee cartilage repair market is estimated at 3.4 billion as of 2020, with arthroscope implants and intrinsic repair technologies accounting for the highest revenue share of the arthroscopy procedures and products market. Vigorous Medical will seamlessly integrate into in this fast-growing market (CAGR 4.87% from 2021 to 2028) by utilizing its proprietary technologies and developing new, cost-effective and off-the-shelf implants.

Skip to content